Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
- PMID: 22878278
- DOI: 10.1164/rccm.201204-0596PP
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Abstract
Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy document for the diagnosis and management of COPD. This executive summary presents the main contents of the second 5-year revision of the GOLD document that has implemented some of the vast knowledge about COPD accumulated over the last years. Today, GOLD recommends that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation. The document highlights that the assessment of the patient with COPD should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities. The first three points can be used to evaluate level of symptoms and risk of future exacerbations, and this is done in a way that splits patients with COPD into four categories-A, B, C, and D. Nonpharmacologic and pharmacologic management of COPD match this assessment in an evidence-based attempt to relieve symptoms and reduce risk of exacerbations. Identification and treatment of comorbidities must have high priority, and a separate section in the document addresses management of comorbidities as well as COPD in the presence of comorbidities. The revised document also contains a new section on exacerbations of COPD. The GOLD initiative will continue to bring COPD to the attention of all relevant shareholders and will hopefully inspire future national and local guidelines on the management of COPD.
Comment in
-
Phosphodiesterase inhibitors in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2013 Dec 1;188(11):1366. doi: 10.1164/rccm.201303-0510LE. Am J Respir Crit Care Med. 2013. PMID: 24289774 No abstract available.
-
GOLD Executive Summary.Am J Respir Crit Care Med. 2013 Dec 1;188(11):1366-7. doi: 10.1164/rccm.201304-0743LE. Am J Respir Crit Care Med. 2013. PMID: 24289775 No abstract available.
-
Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis?Am J Respir Crit Care Med. 2013 Dec 1;188(11):1367. doi: 10.1164/rccm.201305-0927LE. Am J Respir Crit Care Med. 2013. PMID: 24289776 No abstract available.
-
Reply: Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis?Am J Respir Crit Care Med. 2013 Dec 1;188(11):1368. doi: 10.1164/rccm.201307-1263LE. Am J Respir Crit Care Med. 2013. PMID: 24289778 No abstract available.
Similar articles
-
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Eur Respir J. 2017 Mar 6;49(3):1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Eur Respir J. 2017. PMID: 28182564
-
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7. Respirology. 2017. PMID: 28150362
-
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP. Am J Respir Crit Care Med. 2017. PMID: 28128970
-
The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?Clin Respir J. 2012 Oct;6(4):208-14. doi: 10.1111/crj.12002. Clin Respir J. 2012. PMID: 22906068 Review.
-
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16. Am J Respir Crit Care Med. 2007. PMID: 17507545 Review.
Cited by
-
Association between systemic inflammatory markers and chronic obstructive pulmonary disease: A population-based study.Heliyon. 2024 May 18;10(10):e31524. doi: 10.1016/j.heliyon.2024.e31524. eCollection 2024 May 30. Heliyon. 2024. PMID: 38818179 Free PMC article.
-
The Post-COVID-19 Haul on Pulmonary Function: A Prospective Cross-Sectional Study.Cureus. 2024 May 26;16(5):e61101. doi: 10.7759/cureus.61101. eCollection 2024 May. Cureus. 2024. PMID: 38813071 Free PMC article.
-
Management Reality of Female Patients with COPD: A Multicenter Cross-Sectional CAP Study in Japan.Int J Chron Obstruct Pulmon Dis. 2024 May 23;19:1123-1130. doi: 10.2147/COPD.S455397. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38803411 Free PMC article.
-
Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients.Front Med (Lausanne). 2024 May 13;11:1321371. doi: 10.3389/fmed.2024.1321371. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38803343 Free PMC article.
-
Evaluating palliative care case conferences in primary care for patients with advanced non-malignant chronic conditions: a cluster-randomised controlled trial (KOPAL).Age Ageing. 2024 May 1;53(5):afae100. doi: 10.1093/ageing/afae100. Age Ageing. 2024. PMID: 38783755 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical